Skip to main content

Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.

Publication ,  Journal Article
Sathya, G; Chang, C-Y; Kazmin, D; Cook, CE; McDonnell, DP
Published in: Cancer Res
November 15, 2003

The androgen receptor (AR), a member of the nuclear receptor family, is a ligand-inducible transcription factor. In the prostate gland, androgens regulate the transcription of several genes that ultimately result in cell growth and differentiation. With a goal of developing tissue-selective AR modulators that can be used to treat prostate cancer and other androgenopathies, we have taken an approach to identify androgens that function in a manner distinct from the physiological androgens testosterone and dihydrotestosterone. Classical AR agonists function by binding to and inducing a conformational change in the receptor. This facilitates the obligate interaction of the amino and carboxyl terminus of the receptor, recruitment of coactivators, and subsequent regulation of target genes. On the basis of this paradigm, we screened a library of potential AR agonists for compounds that induce an "activating" conformational change in the receptor structure but that do not facilitate a high-affinity intermolecular interaction between the amino and carboxyl terminus. Compounds identified in this manner behaved as partial agonists of AR-mediated transcription in a variety of assays. Additional compounds were identified in this screen that did not allow the activation function-2 coactivator pocket to form and were demonstrated to function as weak agonists of AR-mediated transcription. Surprisingly, when we examined the ability of these compounds to induce cell proliferation, we observed that despite having different degrees of partial agonist activities on classical transcriptional responses (i.e., induction of prostate-specific antigen), these compounds were as efficacious as dihydrotestosterone in stimulating proliferation. The unexpected finding that AR-mediated transcription and proliferation can be uncoupled suggests that AR is not used in the same manner in all androgen-regulated biological processes.

Duke Scholars

Published In

Cancer Res

ISSN

0008-5472

Publication Date

November 15, 2003

Volume

63

Issue

22

Start / End Page

8029 / 8036

Location

United States

Related Subject Headings

  • Transfection
  • Transcriptional Activation
  • Receptors, Androgen
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Haplorhini
  • Cell Division
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sathya, G., Chang, C.-Y., Kazmin, D., Cook, C. E., & McDonnell, D. P. (2003). Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res, 63(22), 8029–8036.
Sathya, Ganesan, Ching-yi Chang, Dmitri Kazmin, C Edgar Cook, and Donald P. McDonnell. “Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.Cancer Res 63, no. 22 (November 15, 2003): 8029–36.
Sathya G, Chang C-Y, Kazmin D, Cook CE, McDonnell DP. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res. 2003 Nov 15;63(22):8029–36.
Sathya G, Chang C-Y, Kazmin D, Cook CE, McDonnell DP. Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res. 2003 Nov 15;63(22):8029–8036.

Published In

Cancer Res

ISSN

0008-5472

Publication Date

November 15, 2003

Volume

63

Issue

22

Start / End Page

8029 / 8036

Location

United States

Related Subject Headings

  • Transfection
  • Transcriptional Activation
  • Receptors, Androgen
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Oncology & Carcinogenesis
  • Male
  • Humans
  • Haplorhini
  • Cell Division